Your Trusted Partner in Cancer Care

ACT Genomics makes personalized medicine accessible to everyone, empowering patients and doctors to stay ahead of cancer.

Our Mission

To Make Personalized Medicine Accessible to All

We use cutting-edge genomic testing to create tailored treatment plans that are precise, fast, and reliable.

With roots in Asia and a commitment to constant innovation, we collaborate closely with our network of experts in cancer biology, genomics, and bioinformatics to lead the way in optimizing cancer management.

Our Values

Prioritize Patients with Care

We care for our patients and place their well-being as our utmost priority. This philosophy ensures that every decision, technology, and service is geared toward providing the best possible care and support to those battling cancer.

Build Trust Through Teamwork

We foster a culture of teamwork and open communication to facilitate seamless collaboration and achieve extraordinary results. This approach helps us establish a reputation for exceptional quality, instilling trust in our patients, partners, and team members.

Progress with Accountability

We create progress and promote positive change by being accountable, transparent, and owning our actions with integrity. This motivates us to commit to our goals, strive for excellence, and establish a strong foundation for growth.

Stay Positive at All Times

We put passion, love, and energy into everything we touch. We believe that upholding a positive attitude enables us to make a real difference and create a welcoming environment where all patients, partners, and staff feel safe and supported.

Our Story

Turn Genomics Into Action

ACT Genomics is an award-winning cancer solution provider founded in 2014 by a small group of scientists from academia. With our name, ACT Genomics, reflecting our passion to “turn genomics into action”, we set out to apply academic theories in clinical practice and truly make personalized cancer care accessible to all.

Over the years, our practical experience has helped academic research make remarkable progress, which has in turn enhanced our cancer solutions with high efficiency and accuracy. As a pioneer in Taiwan and the wider Asian region, we are committed to empowering cancer patients with advanced genomic treatments and continuing to make strides forward in precision medicine.

Management

Walt Ling

Chief Executive Officer

Hua Chien Chen

Chief Scientific Officer & Co-Founder

Victor Chan

Chief Financial Officer

Advisory

Shu Jen Chen

Chief Advisor

Frank S. Ong

Chief Physician Advisor

Milestones

2014

08

ACT Genomics NGS laboratory opens

10

Establishes bioinformatics platform

10

ACT Genomics Singapore branch opens

2015

2016

04

Acquires CAP (NGS) laboratory certification

09

ACT Genomics Hong Kong branch opens
‍
ACT Genomics forms its subsidiary in Shanghai

12

Receives the Symbol of National Quality in Taiwan

03

ACT Genomics Japan branch opens
‍
ACT Genomics receives Frost & Sullivan Product LineStrategy Leadership Award (Molecular Diagnostics)

2017

2018

07

ACT Genomics enters into a joint venture with Canon Medical System Corporation named ACTmed

12

ACTOnco®+ receives National Innovation Award in Taiwan

04

ACTmed establishes an analysis laboratory named "Shonan iPark Laboratory" in "Shonan Health Innovation Park" in Kanagawa, Japan

07

ACT Genomics opens third laboratory in Asia at Hong Kong Science & Technology Park

ACT Genomics wins Taiwan Bio Industry Organization Awards- Emerging Company of the Year

ACT Genomics forms a collaboration with AIA Hong Kong to promote precision cancer medicine

11

ACT Genomics wins the Golden Torch Award of "Annual Top 10 Enterprise" in Taiwan

12

ACT Genomics wins 2019 National Innovation Award in Taiwan

2019

2020

03

ACT Genomics partners with Oncoshot to drive clinical trials at a strategic level in Singapore

05

ACT Genomics is the first to receive approval for laboratory-developed NGS tests and services (LDTS) in Taiwan

09

ACT Genomics and Nan Shan Life Insurance cooperate to promote high-quality cancer precision medicine services in Taiwan

11

ACT Genomics becomes a member of The Global Alliance For Genomics And Health (GA4GH)

ACT Genomics acquires ISO/IEC 27001 certification

06

ACT Genomics completes acquisition of MC Diagnostics

ACT Genomics Hong Kong Lab Limited acquires CAP Laboratory Certification

07

ACT Genomics receives 2021 Frost & Sullivan Best Practices Award

08

CerbACT Asia – a joint venture between ACT Genomics and Cerba Research – is formed to establish a new and top-notched facility in Taipei

11

ACT Genomics acquires Sanomics

2021

2022

02

ACT Genomics' Thailand subsidiary acquires ISO 15189:2012 accreditation

04

ACT Genomics' Thailand subsidiary acquires ISO 15190:2003 accreditation

12

Prenetics Global Limited (NASDAQ: PRE) acquires a majority stake in ACT Genomics Holdings Company Limited

01

ACT Genomics receives clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco®

2023

Contact Our Experts

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Inquire

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Deny Accept

Solutions

Insights

About

Contact

Portal